

Among patients with measurable assays the youngest was 1 year old and the oldest 83 years, with an average age of 33.2 years. Mean assay level was 3.5×10^6 IU/ml while the highest was 1.5×10^8 IU/ml and the lowest 20 IU/ml. The modal class was 31–40 years [Table 4].

Discussion

There is a preponderance of males among HBV-infected persons with detectable VL as seen in this study. Although the reason is not clear, similar finding has been documented in previous studies.^[30,31] Okwurawe *et al.*^[11] had similar finding in Lagos and suggested it could be due to increased financial resources available to males to go for tests as against women. In contrast, Onwuliri *et al.*^[31] and Okonko *et al.*^[32] found more females with HBV infection among HIV patients and blood donors, respectively. A well-designed study may be needed to determine whether women abort the infection better than men.

The modal age range for measurable VL was 31–40 years, similar to 30–39 years obtained in Lagos^[11] and 36–50 years in Bangladesh.^[33] This may be related to the higher incidence of activities associated with HBV acquisition or reactivation of existing infections in this age group.^[34,35] The highest mean was in the 1–10 year group, and was possibly associated with high perinatal transmission and a less competent immune status.^[36] The net effect of this is that there were significantly higher VLs among subjects < 30 years, notwithstanding that the modal age for detection was in the 31–40 years modal group.

Effective management of HBV infection requires HBV DNA VL assay in accordance with existing treatment guidelines. A current guideline developed by the Society for Gastroenterology and Hepatology in Nigeria (SOGHIN) considers HBeAg status a major factor but discounts age.^[13] In HBeAg-positive cases, the critical VL level is 2.0×10^4 IU/ml. VL above this level with abnormal liver enzymes is an indication for chemotherapy, while

VL $< 2.0 \times 10^4$ IU/ml with abnormal liver enzymes needs liver biopsy before chemotherapy can be considered. If patient is HBeAg negative, the critical VL level is 2.0×10^3 IU/ml. A VL greater than this in combination with abnormal liver enzymes supports therapy, but if VL $< 2.0 \times 10^3$ IU/ml a liver histology is needed. Only in the presence of moderate to severe fibrosis is chemotherapy indicated.

Under the SOGHIN guidelines, assuming all patients were HBeAg-positive with an abnormal alanine aminotransferase (ALT) level, 74.0% who have VL $< 2.0 \times 10^4$ IU/ml would need a liver biopsy for further assessment while 16.7% would qualify for chemotherapy based on their DNA and abnormal ALT alone. On the other hand if it is taken that all the patients were HBeAg negative with abnormal ALT levels, then 33.1% would qualify for chemotherapy while 57.6% would need a liver biopsy for determination of appropriate therapy. Therefore, it follows that a large number of patients would be subjected to liver biopsy with its attendant risk.^[37] This would appear to be a challenge in using the SOGHIN guidelines despite its advantage that a single VL and liver function tests could be used to determine therapy.

The National Institute for Health and Care Excellence (NICE) guidelines recognize VL values of 2.0×10^3 – 2.0×10^4 IU/ml as critical cutoff points when considering therapy, in conjunction with age, ALT levels, pregnancy/breastfeeding, and liver histology.^[22] In patients aged ≥ 30 years, with VL $> 2.0 \times 10^3$ IU/ml and ALT > 30 IU/l (male) or > 19 IU/l (females) on two consecutive occasions at least 3 months apart chemotherapy is indicated. However, when the patient is < 30 years with similar findings, an abnormal liver biopsy is needed before considering chemotherapy. In cases where VL $> 2.0 \times 10^4$ IU/ml with abnormal ALT levels, then chemotherapy is indicated. Cases of active liver disease with VL $> 2.0 \times 10^3$ IU/ml or cirrhosis with any VL level also require therapy.

The slightly different approach followed by the NICE guidelines means that if all patients' ALT levels are taken as abnormal, then 23.3% would be placed on chemotherapy among those aged ≥ 30 years while 13.0% of those aged < 30 years would need a liver biopsy for further assessment and subsequent management. 20.3% would be eligible regardless of age for chemotherapy since their VL is $> 2.0 \times 10^4$ IU/ml. In effect the NICE guidelines may be associated with fewer liver biopsies.

The highest measurable VL load range was recorded in the 1–10 years age group. This is where the widest variation

Table 3: Profile of hepatitis B viral load results

VL range	Number (%)
ND	62 (9.3)
<20	72 (10.8)
$20-2 \times 10^3$	312 (46.8)
$2001-2 \times 10^4$	109 (16.4)
$> 2 \times 10^4 - > 1.7 \times 10^8$	111 (16.7)
Total	666 (100)

ND: HBV DNA not detected in sample, HBV: Hepatitis B virus, VL: Viral load

Table 4: Distribution of measurable viral load parameters by age groups (n=276)

Mean VL	Age groups						
	1-10	11-20	21-30	31-40	41-50	51-60	>60
	3.6×10^7	1.7×10^7	2.4×10^6	2.1×10^6	6.2×10^6	2.8×10^5	632
Viral load range	$48-1.5 \times 10^8$	$20-1.3 \times 10^8$	$26-6.8 \times 10^7$	$28-7.4 \times 10^7$	$21-5.6 \times 10^7$	$124-3.9 \times 10^6$	$63-2.1 \times 10^3$
Number of patients	15	38	65	79	58	15	6

VL: Viral load

occurred. This can be explained by the relatively naïve immune system in children and the different clinical course of the infection in this age group.^[33,36,38] This emphasizes the need for both maternal and childhood vaccination against HBV infection.^[10,27,36,38] The retrospective nature of this work is a major limitation, however the information to the scientific community is very relevant to patient management.

Conclusion

VL testing is important in making management decisions in HBV infection. It will help to avoid unnecessary therapies, commence treatment as appropriate, and save cost. More research is needed to further fine-tune the local guidelines. Access to HBV DNA assay needs to be increased through some kind of support to enhance quality of care and research.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

- Nwokediuko SC. Chronic hepatitis B: Management challenges in resource-poor countries. *Hepat Mon* 2011;11:786-93.
- Susmann NL. Treatment of hepatitis B virus infection. *Adv Stud Med* 2009;9:89-95. Available from: http://www.jhasim.com/files/articlefiles/pdf/ASIM_V9-3_article1.pdf. [Last cited on 2015 Mar 13, 12:00 pm].
- Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. *Hepatology* 2009;50:661-2.
- Bárcena Marugán R, García Garzón S. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. *World J Gastroenterol* 2009;15:423-30.
- European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* 2012;57:167-85.
- World Health Organization. Hepatitis B, Fact Sheet No. 204; July, 2012. Available from: <http://www.who.int/mediacentre/factsheets/fs204/en/index.html>. [Last updated on 2015 March; Last cited on 2015 Mar 13, 01:00 pm].
- Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. *J Gastroenterol Hepatol* 2009;24:1179-86.
- Koyuncuer A. Associations between HBeAg status, HBV DNA, ALT level and liver histopathology in patients with chronic hepatitis B. *Sci J Clin Med* 2014;3:117-23. Available from: <http://www.sciencepublishinggroup.com/j/sjcm>. [Last cited on 2015 Mar 13, 01:00 pm].
- Kumar M, Singh T, Sinha S. Chronic hepatitis B virus infection and pregnancy. *J Clin Exp Hepatol* 2012;2:366-81. doi: 10.1016/j.jceh.2012.09.001 [Last cited on 2015 Mar 14, 09:00 am].
- Shimakawa Y, Bottomley C, Njie R, Mendy M. The association between maternal hepatitis B e antigen status, as a proxy for perinatal transmission, and the risk of hepatitis B e antigenaemia in Gambian children. *BMC Public Health* 2014;14:532.
- Okwuraiwe AP, Salu OB, Onwuamah CK, Amoo OS, Oduunukwe NN, Audu RA. Experience with hepatitis B viral load testing in Nigeria. *Afr J Clin Exp Microbiol* 2011;12:101-5. doi: 10.4314/ajcem.v12i3.3 [Last cited on 2015 Mar 14, 10:00 am].
- Society for Gastroenterology and Hepatology in Nigeria (SOGHIN). Hepatitis B and C Treatment Guidelines for Nigeria compiled by SOGHIN, the 2nd Scientific and AGM. Benin; 2009. Available from: <http://www.soghin.org/images/s37>. [Last cited on 2015 Mar 14, 10:00 am].
- Ayoub WS, Keefe EB. Review article: Current antiviral therapy of chronic hepatitis B. *Aliment Pharmacol Ther* 2011;34:1145-58.
- Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, *et al*. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. *Hepatol Int* 2012;6:531-61.
- Leuangerun S, Sriprayoon T. Patterns of hepatitis B viral load level (HBV DNA), hepatitis B e antigen (HBeAg) status and risk factors of cirrhosis and hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients in Thailand. *Int J Infect Dis* 2012;16:e94. Available from: [http://www.ijidonline.com/article/S1201-9712\(12\)00370-0/pdf](http://www.ijidonline.com/article/S1201-9712(12)00370-0/pdf). [Last cited on 2015 Mar 17, 11:00 am].
- Martinot-Peignoux M, Lapalus M, Laouéan C, Lada O, Netto-Cardoso AC, Boyer N, *et al*. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. *J Clin Virol* 2013;58:401-7.
- Lau GK, Wang FS. Management of chronic hepatitis B e antigen-negative disease: Another step forward. *J Infect Dis* 2012;205:7-9.
- Halegoua-De Marzio D, Hann HW. Then and now: The progress in hepatitis B treatment over the past 20 years. *World J Gastroenterol* 2014;20:401-13.
- Tran TT. Immune tolerant hepatitis B: A clinical dilemma. *Gastroenterol Hepatol (N Y)* 2011;7:511-6.
- Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, *et al*. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. *Gastroenterology* 2010;138:1747-54.
- NICE Clinical Guideline 165 – Hepatitis B (chronic); June, 2013. Available from: <http://www.nice.org.uk/nicemedia/live/14191/64234/64234.pdf>. [Last cited on 2015 Mar 17, 12:00 pm].
- Yu SJ, Kim YJ. Hepatitis B viral load affects prognosis of hepatocellular carcinoma. *World J Gastroenterol* 2014;20:12039-44.
- Li MR, Chen GH, Cai CJ, Wang GY, Zhao H. High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence. *Digestion* 2011;84:134-41.
- Lin CL, Kao JH. Risk stratification for hepatitis B virus related hepatocellular carcinoma. *Gastroenterology* 2012;142:1140-9. e3. Available from: <http://www.onlinelibrary.wiley.com/doi/10.1111/jgh.12010/epdf>. [Last cited on 2015 Mar 17, 12:00 pm].
- Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, *et al*. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. *Gastroenterology* 2011;141:1240-8, 1248.e1-2.
- Puoti C. HBsAg carriers with normal ALT levels: Healthy carriers or true patients? *BJMP* 2013;6:a609. Available from:

- <http://www.bjamp.org/files/2011-4-3/bjamp-2011-4-3-a436.pdf>. [Last cited on 2015 Mar 17, 02:00 pm].
27. Jatau ED, Yabaya A. Sero prevalence of hepatitis B virus in pregnant women attending a clinic in Zaria, Nigeria. *Sci World J* 2009;4:7-9. Available from: <http://www.scienceworldjournal.org/article/view/5008>. [Last cited on 2015 Mar 18, 09:00 am].
 28. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. *Hepatology* 2010;51:435-44.
 29. Alao O, Okwori E, Egwu C, Audu F. Seroprevalence of hepatitis B surface antigen among prospective blood donors in an urban area of Benue state. *Internet J Hematol* 2010;5:2. Available from: <https://www.ispub.com/IJHE/5/2/3040>. [Last cited on 2015 Mar 18, 10:00 am].
 30. Amidu N, Alhassan A, Obirikorang C, Feglo P, Majeed SF, Afful D. Sero-prevalence of hepatitis B surface (HBsAg) antigen in three densely populated communities in Kumasi, Ghana. *J Med Biomed Sci* 2012;1:59-65. Available from: <http://www.ajol.info/index.php/jmbs/article/view/77553>. [Last cited on 2015 Mar 18, 11:00 am].
 31. Onwuliri EA, Ndako JA, Dimlong MY. Seroprevalence of hepatitis B surface antigen (1553-9865) [HBsAg] co-infections among HIV positive individuals. *Researcher* 2014;6:74-9. Available from: http://www.sciencepub.net/researcher/research0608/013_26579research060814_74_79.pdf. [Last cited on 2015 Mar 18, 11:00 am].
 32. Okonko IO, Okerentugba PO, Adeniji FO, Anugweje KC. Detection of HBsAg among intending apparently well healthy blood donors. *Nat Sci* 2012;10:69-75. Available from: http://www.sciencepub.net/nature/ns1004/011_7617ns1004_69_75.pdf. [Last cited on 2015 Mar 18, 11:00 am].
 33. Uddin PK, Rabby A, Begum SM, Kabir Y, Rahman M, Absar N. Hepatitis B viral load (HBV-DNA) with age and sex stratifications in Bangladeshi people. *J Med Microbiol Diagn* 2014;3:104. Available from: <http://www.omicsonline.org/open-access/hepatitis-b-viral-load-hbv-dna-with-age-and-sex-stratifications-in-bangladeshi-people-2161-0703.1000144.pdf>. [Last cited on 2015 Mar 18, 12:00 pm].
 34. Hayer J, Jadeau F, Deléage G, Kay A, Zoulim F, Combet C. HBVdb: A knowledge database for hepatitis B virus. *Nucleic Acids Res* 2013;41:D566-70.
 35. Krajden M, McNabb G, Petric M. The laboratory diagnosis of hepatitis B virus. *Can J Infect Dis Med Microbiol* 2005;16:65-72.
 36. Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, Murray KF, *et al*. Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options. *Hepatology* 2010;52:2192-205.
 37. Soresi M, Giannitrapani L, Cervello M, Licata A, Montalto G. Non invasive tools for the diagnosis of liver cirrhosis. *World J Gastroenterol* 2014;20:18131-50.
 38. Lemoine M, Eholié S, Lacombe K. Reducing the neglected burden of viral hepatitis in Africa: Strategies for a global approach. *J Hepatol* 2015;62:469-76.